Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Steroid refractory Acute Graft versus host Disease
1 trial -
MEP
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE
Pfizer Australia Pty Ltd
Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)
1 trial -
METHOTREXATE, IFOSFAMIDE, VINCRISTINE, CYCLOPHOSPHAMIDE, RITUXIMAB, ETOPOSIDE, CYTARABINE, PREDNISOLONE, DOXORUBICIN
Wuhan Createrna Science and Technology Co., Ltd
Burkitt lymphoma
1 trial -
METHOTREXATE, METHOTREXATE, DESOXIMETASONE, TACROLIMUS, placebo, Acidum folicum Léčiva 10 mg obalené tablety, FOLIC ACID
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
moderate to severe atopic dermatitis
1 trial -
METHYLPREDNISOLONE, Placebo of CRESEMBA, CRESEMBA 200 mg powder for concentrate for solution for infusion, Placebo of methylprednisolone
Pari Pharma GmbH
patients with acute respiratory failure from undetermined etiology
1 trial -
METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE
Novartis Pharmaceuticals
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
1 trial -
MIE
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Carcinoma
1 trial -
MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084
Merck Sharp and Dohme
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
1 trial -
MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN
Merck Sharp and Dohme
Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer
1 trial -
MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED
Merck Sharp and Dohme
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])
1 trial -
MK-3475A, PEMETREXED , MK-1084, MK-1084, CISPLATIN , CARBOPLATIN , MK-1084, MK-1084
Merck Sharp and Dohme
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
1 trial -
MORPHINE SULFATE, Placebo tablets morphine sulfate 10mg
Pari Pharma GmbH
patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis.
1 trial -
MPs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematological Diseases
1 trial -
MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL
Bristol-Myers Squibb Australia Pty Ltd
metastatic non-small cell lung cancer
1 trial -
MTX
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gestational Trophoblastic Tumor
1 trial -
MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
Megestrol(Yining)
The First People's Hospital of Lianyungang
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Mesenchymal Stromal Cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Graft-Versus-Host Disease
1 trial -
Metformin plus pioglitazone
The First People's Hospital of Lianyungang
Type 2 Diabetes
1 trial -
Metformina Uxa 850 mg comprimidos recubiertos con película EFG, El producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur, acondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo.
The George Institute
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Methylprednisolone pulse
The First People's Hospital of Lianyungang
Glomerulonephritis, IGA
1 trial -
Methylprednisolone sodium succinate
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources